IT201800009731A1 - Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante - Google Patents

Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante Download PDF

Info

Publication number
IT201800009731A1
IT201800009731A1 IT102018000009731A IT201800009731A IT201800009731A1 IT 201800009731 A1 IT201800009731 A1 IT 201800009731A1 IT 102018000009731 A IT102018000009731 A IT 102018000009731A IT 201800009731 A IT201800009731 A IT 201800009731A IT 201800009731 A1 IT201800009731 A1 IT 201800009731A1
Authority
IT
Italy
Prior art keywords
treatment
pharmaceutical composition
paclitaxel
prodrug
weight
Prior art date
Application number
IT102018000009731A
Other languages
English (en)
Italian (it)
Inventor
Giorgio Mosconi
Daniela Jabes
Carlo Pizzocaro
Original Assignee
Fidia Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farm Spa filed Critical Fidia Farm Spa
Priority to IT102018000009731A priority Critical patent/IT201800009731A1/it
Priority to PL19801630.5T priority patent/PL3870233T3/pl
Priority to PCT/IB2019/059073 priority patent/WO2020084525A1/en
Priority to CN201980064603.9A priority patent/CN112805035A/zh
Priority to RS20240122A priority patent/RS65193B1/sr
Priority to US16/959,979 priority patent/US20200397909A1/en
Priority to EA202190614A priority patent/EA202190614A1/ru
Priority to HRP20240188TT priority patent/HRP20240188T1/hr
Priority to JP2021515655A priority patent/JP7518815B2/ja
Priority to SM20240021T priority patent/SMT202400021T1/it
Priority to CN202510138513.7A priority patent/CN119792555A/zh
Priority to KR1020217007729A priority patent/KR102913965B1/ko
Priority to PT198016305T priority patent/PT3870233T/pt
Priority to MA63879A priority patent/MA63879B1/fr
Priority to HUE19801630A priority patent/HUE066288T2/hu
Priority to DK19801630.5T priority patent/DK3870233T3/da
Priority to EP19801630.5A priority patent/EP3870233B1/en
Priority to ES19801630T priority patent/ES2971217T3/es
Priority to LTEPPCT/IB2019/059073T priority patent/LT3870233T/lt
Priority to FIEP19801630.5T priority patent/FI3870233T3/fi
Priority to CA3112188A priority patent/CA3112188A1/en
Priority to SI201831054T priority patent/SI3870233T1/sl
Publication of IT201800009731A1 publication Critical patent/IT201800009731A1/it
Priority to US17/204,183 priority patent/US20210196833A1/en
Priority to US17/315,962 priority patent/US12465649B2/en
Priority to US18/539,827 priority patent/US20240123077A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT102018000009731A 2018-10-25 2018-10-25 Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante IT201800009731A1 (it)

Priority Applications (25)

Application Number Priority Date Filing Date Title
IT102018000009731A IT201800009731A1 (it) 2018-10-25 2018-10-25 Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante
KR1020217007729A KR102913965B1 (ko) 2018-10-25 2019-10-23 비근육 침습성 방광암 치료 시의 파클리탁셀-히알루론산 접합체
MA63879A MA63879B1 (fr) 2018-10-25 2019-10-23 Conjugué de paclitaxel et d'acide hyaluronique dans le traitement du cancer de la vessie sans infiltration du muscle
CN201980064603.9A CN112805035A (zh) 2018-10-25 2019-10-23 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物
RS20240122A RS65193B1 (sr) 2018-10-25 2019-10-23 Konjugat paklitaksel-hijaluronska kiselina u lečenju nemišićno invazivnog kancera bešike
US16/959,979 US20200397909A1 (en) 2018-10-25 2019-10-23 Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
EA202190614A EA202190614A1 (ru) 2018-10-25 2019-10-23 Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря
HRP20240188TT HRP20240188T1 (hr) 2018-10-25 2019-10-23 Konjugat paklitaksel-hijaluronska kiselina u liječenju nemišićno invazivnog raka mjehura
JP2021515655A JP7518815B2 (ja) 2018-10-25 2019-10-23 筋層非浸潤性膀胱がんの治療におけるパクリタキセル-ヒアルロン酸複合体
SM20240021T SMT202400021T1 (it) 2018-10-25 2019-10-23 Coniugato paclitaxel-acido ialuronico nel trattamento del carcinoma vescicale non muscolo-invasivo
CN202510138513.7A CN119792555A (zh) 2018-10-25 2019-10-23 用于治疗非肌层浸润性膀胱癌的紫杉醇-透明质酸缀合物
PL19801630.5T PL3870233T3 (pl) 2018-10-25 2019-10-23 Koniugat paklitakselu z kwasem hialuronowym do leczenia raka pęcherza moczowego nienaciekającego mięśniówki
PT198016305T PT3870233T (pt) 2018-10-25 2019-10-23 Conjugado de paclitaxel-ácido hialurónico no tratamento de cancro da bexiga não-músculo invasivo
DK19801630.5T DK3870233T3 (da) 2018-10-25 2019-10-23 Paclitaxel-hyaluronsyrekonjugat til behandlingen af ikke-muskelinvasiv blærekræft
HUE19801630A HUE066288T2 (hu) 2018-10-25 2019-10-23 Paclitaxel-hialuronsav konjugátum nem-izom invazív húgyhólyagrák kezelésében
CA3112188A CA3112188A1 (en) 2018-10-25 2019-10-23 Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
EP19801630.5A EP3870233B1 (en) 2018-10-25 2019-10-23 Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
ES19801630T ES2971217T3 (es) 2018-10-25 2019-10-23 Conjugado de paclitaxel-ácido hialurónico en el tratamiento del cáncer de vejiga no músculo invasivo
LTEPPCT/IB2019/059073T LT3870233T (lt) 2018-10-25 2019-10-23 Paklitakselio ir hialurono rūgšties konjugatas, skirtas į raumenis neplintančio šlapimo pūslės vėžio gydymui
FIEP19801630.5T FI3870233T3 (fi) 2018-10-25 2019-10-23 Paklitakseli-Hyaluronihapon konjugaatti käytettäväksi ei-lihasinvasiivisen virtsarakon syövän hoidossa
PCT/IB2019/059073 WO2020084525A1 (en) 2018-10-25 2019-10-23 Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
SI201831054T SI3870233T1 (sl) 2018-10-25 2019-10-23 Konjugat paklitaksel-hialuronske kisline za zdravljenje nemišično invazivnega raka mehurja
US17/204,183 US20210196833A1 (en) 2018-10-25 2021-03-17 Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
US17/315,962 US12465649B2 (en) 2018-10-25 2021-05-10 Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
US18/539,827 US20240123077A1 (en) 2018-10-25 2023-12-14 Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102018000009731A IT201800009731A1 (it) 2018-10-25 2018-10-25 Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante

Publications (1)

Publication Number Publication Date
IT201800009731A1 true IT201800009731A1 (it) 2020-04-25

Family

ID=65324453

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102018000009731A IT201800009731A1 (it) 2018-10-25 2018-10-25 Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante

Country Status (21)

Country Link
US (4) US20200397909A1 (https=)
EP (1) EP3870233B1 (https=)
JP (1) JP7518815B2 (https=)
KR (1) KR102913965B1 (https=)
CN (2) CN112805035A (https=)
CA (1) CA3112188A1 (https=)
DK (1) DK3870233T3 (https=)
EA (1) EA202190614A1 (https=)
ES (1) ES2971217T3 (https=)
FI (1) FI3870233T3 (https=)
HR (1) HRP20240188T1 (https=)
HU (1) HUE066288T2 (https=)
IT (1) IT201800009731A1 (https=)
LT (1) LT3870233T (https=)
MA (1) MA63879B1 (https=)
PL (1) PL3870233T3 (https=)
PT (1) PT3870233T (https=)
RS (1) RS65193B1 (https=)
SI (1) SI3870233T1 (https=)
SM (1) SMT202400021T1 (https=)
WO (1) WO2020084525A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000007747A1 (it) * 2020-04-10 2021-10-10 Fidia Farm Spa Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma
IT202000008209A1 (it) * 2020-04-17 2021-10-17 Fidia Farm Spa Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138572A2 (en) 1983-10-11 1985-04-24 FIDIA S.p.A. Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
EP0716688A1 (en) 1993-07-30 1996-06-19 Fidia Advanced Biopolymers S.R.L. Process for the preparation and purification of high molecular weight hyaluronic acid
WO2004035629A2 (en) * 2002-10-18 2004-04-29 Fidia Farmaceutici S.P.A. Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
EP2614088A1 (en) 2010-09-09 2013-07-17 Fidia Farmaceutici S.p.A. Process for the production of hyaluronic acid in escherichia coli or bacillus subtilis
EP2614087A1 (en) 2010-09-09 2013-07-17 Fidia Farmaceutici S.p.A. Process for the production of hyaluronic acid in escherichia coli or bacillus megaterium
WO2018020458A1 (en) 2016-07-28 2018-02-01 Fidia Farmaceutici S.P.A. Process for the preparation and purification of the sodium salt of hyaluronic acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
ITMI20071267A1 (it) 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
EP3290511B1 (en) 2011-11-09 2020-08-26 Spinalcyte, LLC Dermal fibroblasts for treatment of degenerative disc disease
CN110859962B (zh) 2019-11-25 2021-01-22 山东大学 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138572A2 (en) 1983-10-11 1985-04-24 FIDIA S.p.A. Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
EP0716688A1 (en) 1993-07-30 1996-06-19 Fidia Advanced Biopolymers S.R.L. Process for the preparation and purification of high molecular weight hyaluronic acid
WO2004035629A2 (en) * 2002-10-18 2004-04-29 Fidia Farmaceutici S.P.A. Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
EP2045270A2 (en) 2002-10-18 2009-04-08 FIDIA FARMACEUTICI S.p.A. Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
EP2614088A1 (en) 2010-09-09 2013-07-17 Fidia Farmaceutici S.p.A. Process for the production of hyaluronic acid in escherichia coli or bacillus subtilis
EP2614087A1 (en) 2010-09-09 2013-07-17 Fidia Farmaceutici S.p.A. Process for the production of hyaluronic acid in escherichia coli or bacillus megaterium
WO2018020458A1 (en) 2016-07-28 2018-02-01 Fidia Farmaceutici S.P.A. Process for the preparation and purification of the sodium salt of hyaluronic acid

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BASSI P F ET AL: "Paclitaxel-Hyaluronic Acid for Intravesical Therapy of Bacillus Calmette-Guerin Refractory Carcinoma In Situ of the Bladder: Results of a Phase I Study", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 185, no. 2, 1 February 2011 (2011-02-01), pages 445 - 449, XP027595068, ISSN: 0022-5347, [retrieved on 20110109], DOI: 10.1016/J.JURO.2010.09.073 *
HUIZING MT ET AL., CANCER INV, vol. 13, 1995, pages 381 - 404
ISABELLA MONIA MONTAGNER ET AL: "Paclitaxel-hyaluronan hydrosoluble bioconjugate: Mechanism of action in human bladder cancer cell lines", UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS, vol. 31, no. 7, 1 October 2013 (2013-10-01), AMSTERDAM, NL, pages 1261 - 1269, XP055414808, ISSN: 1078-1439, DOI: 10.1016/j.urolonc.2012.01.005 *
LUO ET AL., BIOMACROMOLECULES, vol. 1, no. 2, 2000, pages 208 - 218
MANFREDI JJ ET AL., J CELL BIOL, vol. 94, 1982, pages 688 - 696
MONICA CAMPISI ET AL: "ONCOFID(TM)-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis", CURRENT BIOACTIVE COMPOUNDS, vol. 7, no. 1, 1 March 2011 (2011-03-01), pages 27 - 32, XP055599334, ISSN: 1573-4072, DOI: 10.2174/157340711795163848 *
NUIJEN B ET AL., INVESTIGATIONAL NEW DRUGS, vol. 19, 2001, pages 143 - 153
ROSATO A ET AL: "HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer", UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 3, 1 May 2006 (2006-05-01), pages 207 - 215, XP028071920, ISSN: 1078-1439, [retrieved on 20060501], DOI: 10.1016/J.UROLONC.2005.08.020 *
TERBOJEVICH ET AL., CARBOHYDR RES, 1986, pages 363 - 377

Also Published As

Publication number Publication date
CN119792555A (zh) 2025-04-11
SI3870233T1 (sl) 2024-03-29
US20210268119A1 (en) 2021-09-02
EP3870233A1 (en) 2021-09-01
PL3870233T3 (pl) 2024-05-06
EA202190614A1 (ru) 2021-06-03
DK3870233T3 (da) 2024-02-05
US20200397909A1 (en) 2020-12-24
US12465649B2 (en) 2025-11-11
ES2971217T3 (es) 2024-06-04
SMT202400021T1 (it) 2024-03-13
KR102913965B1 (ko) 2026-01-16
JP2022503771A (ja) 2022-01-12
CN112805035A (zh) 2021-05-14
CA3112188A1 (en) 2020-04-30
FI3870233T3 (fi) 2024-02-07
JP7518815B2 (ja) 2024-07-18
KR20210083249A (ko) 2021-07-06
RS65193B1 (sr) 2024-03-29
HRP20240188T1 (hr) 2024-05-10
US20210196833A1 (en) 2021-07-01
EP3870233B1 (en) 2023-12-06
PT3870233T (pt) 2024-02-01
MA63879B1 (fr) 2024-02-29
LT3870233T (lt) 2024-02-26
US20240123077A1 (en) 2024-04-18
WO2020084525A1 (en) 2020-04-30
HUE066288T2 (hu) 2024-07-28

Similar Documents

Publication Publication Date Title
Goodarzi et al. CD 44‐targeted docetaxel conjugate for cancer cells and cancer stem‐like cells: a novel hyaluronic acid‐based drug delivery system
Qian et al. A paclitaxel‐based mucoadhesive nanogel with multivalent interactions for cervical cancer therapy
Xiong et al. Peptide–Gold Nanoparticle Hybrids as Promising Anti‐Inflammatory Nanotherapeutics for Acute Lung Injury: In Vivo Efficacy, Biodistribution, and Clearance
KR101584384B1 (ko) 종양 형성의 치료에서 히알루론산에 결합된 항종양 약물을 포함하는 신규한 제약학적 조제물의 치료적 용도
US20240123077A1 (en) Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
Haider et al. Thermogelling platform for baicalin delivery for versatile biomedical applications
Qiu et al. Hyaluronic acid-conjugated fluorescent probe-shielded polydopamine nanomedicines for targeted imaging and chemotherapy of bladder cancer
Cho et al. Preparation of sodium deoxycholate (DOC) conjugated heparin derivatives for inhibition of angiogenesis and cancer cell growth
CA2911906A1 (en) Therapeutic and imaging compositions and uses thereof
Zhao et al. ROS/pH dual-responsive quercetin-loaded guanosine borate supramolecular hydrogel enema in dextran sulfate sodium-induced colitis in mice
Tong et al. Amplifying ER Stress via Biodegradable Pseudo‐Conjugated Polymer Nanoparticles for Enhanced Sonodynamic Immunotherapy
Lin et al. Enhancing targeted photodynamic therapy: star-shaped glycopolymeric photosensitizers for improved selectivity and efficacy
Sonvico et al. Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma
CN104398504B (zh) 一种去氧鬼臼毒素类药物的药物组合物及其制备方法和制剂
Wang et al. Blood–brain barrier-permeable, reactive oxygen species-producing, and mitochondria-targeting nanosystem amplifies glioblastoma therapy
Zhang et al. Poly (photosensitizer-prodrug) unimolecular micelles for chemo-photodynamic synergistic therapy of antitumor and antibacteria
Patel et al. Dual stimuli-responsive gemcitabine-conjugated alginate-chitosan nanoparticles for triple-negative breast cancer therapy: A smart approach
IT201900019762A1 (it) Composizione farmaceutica per uso nel trattamento della cistite di varia eziologia
HK40048954B (en) Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
HK40048954A (en) Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer
EA043782B1 (ru) Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря
Kikani et al. Design and Synthesis of an Aggregation-Induced Emission-Active Quad-Functional “Curcumin-Spiced Marvel” for Engineering of Sialic Acid-Targeted Nanoplatform for Cancer Therapy
Ding et al. Glycolysis inhibition via pH-responsive nanoparticles modulates macrophage reprogramming for sepsis immunotherapy
WO2016038534A1 (en) Fenretinide complexes
Zhu Nanoparticles Targeting Tumour Associated Macrophages